Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2007 by Tel-Aviv Sourasky Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT00517101
First received: August 15, 2007
Last updated: NA
Last verified: August 2007
History: No changes posted
  Purpose

A relationship between IBD and spondyloarthropathy is well recognized. ASCA ( anti saccharomyces cerevisiae antibodies)are considered to be a serological marker for Crohn's disease and have been studied in patients with spondyloarthropathy with conflicting results. More recently, new serological markers for IBD have been described. These markers are antibodies to certain defined glycans , and their use may permit an improved diagnosis of IBD.

The aim of our study is to investigate wether these new serological markers are present in the sera of patients with spondyloarthropathy.


Condition
Psoriatic Arthritis
Ankylosing Spondylitis
Undifferentiated Spondyloarthropathy

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal

Resource links provided by NLM:


Further study details as provided by Tel-Aviv Sourasky Medical Center:

Study Start Date: September 2007
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • diagnosis of psoriatic arthritis, ankylosing spondylitis, or undifferentiated spondyloarthropathy

Exclusion Criteria:

  • diagnosed inflammatory bowel disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00517101

Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Investigators
Principal Investigator: valerie aloush, MD Tel-Aviv Sourasky Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00517101     History of Changes
Other Study ID Numbers: TAMSC-07-VA-318-CTIL
Study First Received: August 15, 2007
Last Updated: August 15, 2007
Health Authority: Israel: Ministry of Health

Keywords provided by Tel-Aviv Sourasky Medical Center:
spondyloarthropathy
inflammatory bowel disease
antibodies

Additional relevant MeSH terms:
Bone Diseases, Infectious
Arthritis, Psoriatic
Spondylarthropathies
Spondylitis
Spondylitis, Ankylosing
Ankylosis
Arthritis
Bone Diseases
Infection
Joint Diseases
Musculoskeletal Diseases
Psoriasis
Skin Diseases
Skin Diseases, Papulosquamous
Spinal Diseases
Spondylarthritis

ClinicalTrials.gov processed this record on October 30, 2014